• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Pharma industry news

merck-emend

Phase 3 study of Emend for Injection regimen met primary endpoint

29 June 2015

Merck has announced results from a Phase 3 study investigating single-dose Emend for Injection for the prevention of CINV associated with MEC...

whooping-cough

Whooping cough resurgence due to vaccinated people not knowing they’re infectious?

29 June 2015

Public health officials have blamed the waning effectiveness of the current vaccine and anti-vaccine sentiment as the cause of the whooping cough resurgence...

zealand-hypoglycaemia

Phase I trial results for ZP4207 support its further development as a rescue treatment for severe hypoglycaemia

29 June 2015

Zealand has announced results from a Phase I clinical trial of ZP4207 in severe hypoglycaemia in patients with diabetes...

Orfadin

European Commission approves Orfadin oral suspension

29 June 2015

The European Commission (EC) has approved the oral suspension formulation of Sobi’s Orfadin for the treatment of Hereditary Tyrosinaemia type-1 (HT-1)...

respreeza

CSL Behring receives positive CHMP opinion for Respreeza

29 June 2015

The Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation in the EU for CSL Behring's Respreeza...

perjeta

Perjeta recommended for approval in EU for use before surgery in HER2-positive early breast cancer

29 June 2015

The CHMP has recommended that the EC approves the use of Perjeta for the neoadjuvant treatment of adult patients with HER2-positive early breast cancer...

secukinumab

New results show sustained efficacy with secukinumab over one year in psoriatic arthritis patients

29 June 2015

New one year results from the pivotal Phase III FUTURE 2 study of Novartis’ secukinumab in psoriatic arthritis (PsA) have been published.

novartis-spinifex

Novartis acquires Spinifex Pharmaceuticals

29 June 2015

Novartis has entered into an agreement to acquire Spinifex - a company focused on developing a peripheral approach to treat neuropathic pain...

levemir

Levemir receives positive CHMP opinion for extended use in children as young as one year old

29 June 2015

The CHMP has issued a positive opinion for the expanded use of Novo Nordisk’s Levemir (insulin detemir) in children with diabetes as young as one year old...

strensiq

Alexion receives CHMP positive opinions for Strensiq and Kanuma

26 June 2015

Alexion has announced that the CHMP of the EMA has adopted positive opinions recommending marketing authorisation of Strensiq and Kanuma...

Panobinostat

Panobinostat recommended by CHMP for EU approval to treat multiple myeloma

26 June 2015

The CHMP of the EMA have adopted a positive opinion for panobinostat capsules for the treatment of patients with multiple myeloma...

alprolix

European Medicines Agency validates Alprolix marketing authorisation application

26 June 2015

Biogen and SOBI have announced that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for Alprolix...

 

Don't miss this FREE webinar: Biased ligands in Drug Discovery - the case of TRV027
+ +